Merck KGaA (OTCMKTS:MKGAF) Shares Up 6% – What’s Next?

Merck KGaA (OTCMKTS:MKGAF) was up 6% during trading on Friday. The stock traded as high as $165.6890 and last traded at $165.6890. 23 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 643 shares. The stock had previously closed at $156.2470.

Merck KGaA Stock Up 6.6%

The firm has a market capitalization of $21.52 billion, a P/E ratio of 25.42 and a beta of 0.96. The firm’s 50 day moving average is $159.73 and its two-hundred day moving average is $153.45. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.31 and a quick ratio of 0.84.

Institutional Trading of Merck KGaA

A number of large investors have recently added to or reduced their stakes in the company. North Star Asset Management Inc. bought a new stake in shares of Merck KGaA in the 2nd quarter valued at about $1,411,000. MASTERINVEST Kapitalanlage GmbH bought a new position in Merck KGaA during the second quarter worth about $4,896,000. Ames National Corp bought a new position in Merck KGaA during the second quarter worth about $1,009,000. Elefante Mark B bought a new position in Merck KGaA during the second quarter worth about $617,000. Finally, Pinnacle Holdings LLC acquired a new position in Merck KGaA during the second quarter worth approximately $1,487,000. Institutional investors and hedge funds own 0.10% of the company’s stock.

Merck KGaA Company Profile

Merck KGaA is a Germany-based science and technology company headquartered in Darmstadt. Founded in 1668, it is one of the world’s oldest operating pharmaceutical and chemical companies. Merck KGaA is separate from the U.S.-based Merck & Co, Inc, although the two companies share historical roots.

The company operates through three business sectors: Life Science, Healthcare and Electronics. Its Life Science business supplies laboratory products, research tools, chemicals and bioprocessing technologies used by pharmaceutical, biotechnology and academic customers.